Harvard Bioscience Inc. (NASDAQ:HBIO) has been assigned a $6.00 target price by Benchmark Co. in a note issued to investors on Monday. The firm presently has a “buy” rating on the stock. Benchmark Co.’s price objective indicates a potential upside of 130.77% from the stock’s previous close.

Several other analysts have also recently commented on the company. Singular Research started coverage on Harvard Bioscience in a research report on Thursday. They issued a “buy” rating and a $5.50 target price on the stock. Zacks Investment Research upgraded Harvard Bioscience from a “sell” rating to a “hold” rating in a research report on Wednesday, September 14th.

Harvard Bioscience (NASDAQ:HBIO) traded down 1.92% during trading on Monday, hitting $2.55. The stock had a trading volume of 48,941 shares. The stock’s market cap is $87.65 million. Harvard Bioscience has a 1-year low of $2.25 and a 1-year high of $3.90. The firm’s 50-day moving average price is $2.53 and its 200-day moving average price is $2.87.

In other news, CFO Robert E. Gagnon purchased 25,000 shares of the firm’s stock in a transaction on Thursday, November 3rd. The stock was purchased at an average cost of $2.34 per share, with a total value of $58,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jeffrey Duchemin purchased 15,000 shares of the firm’s stock in a transaction on Thursday, November 3rd. The shares were purchased at an average cost of $2.42 per share, with a total value of $36,300.00. The disclosure for this purchase can be found here. Company insiders own 8.80% of the company’s stock.

A number of institutional investors have recently modified their holdings of HBIO. Panagora Asset Management Inc. raised its position in shares of Harvard Bioscience by 57.1% in the third quarter. Panagora Asset Management Inc. now owns 44,521 shares of the company’s stock worth $121,000 after buying an additional 16,174 shares during the last quarter. D. E. Shaw & Co. Inc. raised its position in shares of Harvard Bioscience by 9.4% in the third quarter. D. E. Shaw & Co. Inc. now owns 75,954 shares of the company’s stock worth $207,000 after buying an additional 6,511 shares during the last quarter. Woodmont Investment Counsel LLC raised its position in shares of Harvard Bioscience by 46.9% in the third quarter. Woodmont Investment Counsel LLC now owns 262,517 shares of the company’s stock worth $714,000 after buying an additional 83,756 shares during the last quarter. Paradigm Capital Management Inc. NY raised its position in shares of Harvard Bioscience by 19.5% in the third quarter. Paradigm Capital Management Inc. NY now owns 581,900 shares of the company’s stock worth $1,583,000 after buying an additional 95,100 shares during the last quarter. Finally, Spark Investment Management LLC raised its position in shares of Harvard Bioscience by 195.7% in the third quarter. Spark Investment Management LLC now owns 103,500 shares of the company’s stock worth $281,000 after buying an additional 68,500 shares during the last quarter. 65.43% of the stock is owned by hedge funds and other institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

5 Day Chart for NASDAQ:HBIO

Receive News & Stock Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related stocks with our FREE daily email newsletter.